Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1986 Nov;78(5):1131–1135. doi: 10.1172/JCI112692

Cancer chemotherapy: new strategies for success.

N A Berger
PMCID: PMC423794  PMID: 3533996

Full text

PDF
1131

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adelstein D. J., Sharan V. M., Earle A. S., Shah A. C., Vlastou C., Haria C. D., Carter S. G., Damm C., Hines J. D. Chemoradiotherapy as initial management in patients with squamous cell carcinoma of the head and neck. Cancer Treat Rep. 1986 Jun;70(6):761–767. [PubMed] [Google Scholar]
  2. Armitage J. O., Fyfe M. A., Lewis J. Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol. 1984 Aug;2(8):898–902. doi: 10.1200/JCO.1984.2.8.898. [DOI] [PubMed] [Google Scholar]
  3. Arrick B. A., Nathan C. F. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 1984 Oct;44(10):4224–4232. [PubMed] [Google Scholar]
  4. Aur R. J., Simone J. V., Hustu H. O., Verzosa M. S. A comparative study of central nervous system irradiation and intensive chemotherapy early in remission of childhood acute lymphocytic leukemia. Cancer. 1972 Feb;29(2):381–391. doi: 10.1002/1097-0142(197202)29:2<381::aid-cncr2820290219>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  5. Baxter J. D., Harris A. W., Tomkins G. M., Cohn M. Glucocorticoid receptors in lymphoma cells in culture: relationship to glucocorticoid killing activity. Science. 1971 Jan 15;171(3967):189–191. doi: 10.1126/science.171.3967.189. [DOI] [PubMed] [Google Scholar]
  6. Berger N. A., Berger S. J., Catino D. M., Petzold S. J., Robins R. K. Modulation of nicotinamide adenine dinucleotide and poly(adenosine diphosphoribose) metabolism by the synthetic "C" nucleoside analogs, tiazofurin and selenazofurin. A new strategy for cancer chemotherapy. J Clin Invest. 1985 Feb;75(2):702–709. doi: 10.1172/JCI111750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Berger N. A., Catino D. M., Vietti T. J. Synergistic antileukemic effect of 6-aminonicotinamide and 1,3-bis(2-chloroethyl)-1-nitrosourea on L1210 cells in vitro and in vivo. Cancer Res. 1982 Nov;42(11):4382–4386. [PubMed] [Google Scholar]
  8. Berger N. A. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res. 1985 Jan;101(1):4–15. [PubMed] [Google Scholar]
  9. Berger N. A., Sikorski G. W., Petzold S. J., Kurohara K. K. Association of poly(adenosine diphosphoribose) synthesis with DNA damage and repair in normal human lymphocytes. J Clin Invest. 1979 Jun;63(6):1164–1171. doi: 10.1172/JCI109410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Berger S. J., Sudar D. C., Berger N. A. Metabolic consequences of DNA damage: DNA damage induces alterations in glucose metabolism by activation of poly (ADP-ribose) polymerase. Biochem Biophys Res Commun. 1986 Jan 14;134(1):227–232. doi: 10.1016/0006-291x(86)90551-6. [DOI] [PubMed] [Google Scholar]
  11. Bertazzoni U., Stefanini M., Noy G. P., Giulotto E., Nuzzo F., Falaschi A., Spadari S. Variations of DNA polymerase-alpha and -beta during prolonged stimulation of human lymphocytes. Proc Natl Acad Sci U S A. 1976 Mar;73(3):785–789. doi: 10.1073/pnas.73.3.785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Biaglow J. E., Varnes M. E., Clark E. P., Epp E. R. The role of thiols in cellular response to radiation and drugs. Radiat Res. 1983 Sep;95(3):437–455. [PubMed] [Google Scholar]
  13. Bishop J. M. Cellular oncogenes and retroviruses. Annu Rev Biochem. 1983;52:301–354. doi: 10.1146/annurev.bi.52.070183.001505. [DOI] [PubMed] [Google Scholar]
  14. Bonadonna G., Rossi A., Tancini G., Valagussa P. Adjuvant chemotherapy in breast cancer. Lancet. 1983 May 21;1(8334):1157–1157. doi: 10.1016/s0140-6736(83)92882-9. [DOI] [PubMed] [Google Scholar]
  15. Broek D., Samiy N., Fasano O., Fujiyama A., Tamanoi F., Northup J., Wigler M. Differential activation of yeast adenylate cyclase by wild-type and mutant RAS proteins. Cell. 1985 Jul;41(3):763–769. doi: 10.1016/s0092-8674(85)80057-x. [DOI] [PubMed] [Google Scholar]
  16. Buroker T. R., Moertel C. G., Fleming T. R., Everson L. K., Cullinan S. A., Krook J. E., Mailliard J. A., Marschke R. F., Klaassen D. J., Laurie J. A. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol. 1985 Dec;3(12):1624–1631. doi: 10.1200/JCO.1985.3.12.1624. [DOI] [PubMed] [Google Scholar]
  17. Carter S. K. Adjuvant chemotherapy in osteogenic sarcoma: the triumph that isn't? J Clin Oncol. 1984 Mar;2(3):147–148. doi: 10.1200/JCO.1984.2.3.147. [DOI] [PubMed] [Google Scholar]
  18. Chabner B. A., Fine R. L., Allegra C. J., Yeh G. W., Curt G. A. Cancer chemotherapy. Progress and expectations, 1984. Cancer. 1984 Dec 1;54(11 Suppl):2599–2608. doi: 10.1002/1097-0142(19841201)54:2+<2599::aid-cncr2820541403>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  19. Clarkson B. D. Acute myelocytic leukemia in adults. Cancer. 1972 Dec;30(6):1572–1582. doi: 10.1002/1097-0142(197212)30:6<1572::aid-cncr2820300624>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  20. Cohen J. J., Catino D. M., Petzold S. J., Berger N. A. Activation of poly(adenosine diphosphate ribose) polymerase by SV 40 minichromosomes: effects of deoxyribonucleic acid damage and histone H1. Biochemistry. 1982 Sep 28;21(20):4931–4940. doi: 10.1021/bi00263a016. [DOI] [PubMed] [Google Scholar]
  21. D'Angio G. J., Evans A., Breslow N., Beckwith B., Bishop H., Farewell V., Goodwin W., Leape L., Palmer N., Sinks L. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer. 1981 May 1;47(9):2302–2311. doi: 10.1002/1097-0142(19810501)47:9<2302::aid-cncr2820470933>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  22. DIETRICH L. S., FRIEDLAND I. M., KAPLAN L. A. Pyridine nucleotide metabolism: mechanism of action of the niacin antagonist, 6-aminonicotinamide. J Biol Chem. 1958 Oct;233(4):964–968. [PubMed] [Google Scholar]
  23. DeVita V. T., Jr, Young R. C., Canellos G. P. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer. 1975 Jan;35(1):98–110. doi: 10.1002/1097-0142(197501)35:1<98::aid-cncr2820350115>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  24. DeVita V. T., Schein P. S. The use of drugs in combination for the treatment of cancer: rationale and results. N Engl J Med. 1973 May 10;288(19):998–1006. doi: 10.1056/NEJM197305102881905. [DOI] [PubMed] [Google Scholar]
  25. Dedrick R. L., Myers C. E., Bungay P. M., DeVita V. T., Jr Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978 Jan;62(1):1–11. [PubMed] [Google Scholar]
  26. Deutsch W. A., Spiering A. L., Newkome G. R. An in vitro characterization of interstrand cross-links in DNA exposed to the antitumor drug cis-dichlorodiammineplatinum(II). Biochem Biophys Res Commun. 1980 Dec 16;97(3):1220–1226. doi: 10.1016/0006-291x(80)91505-3. [DOI] [PubMed] [Google Scholar]
  27. Devita V. T., Jr, Serpick A. A., Carbone P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970 Dec;73(6):881–895. doi: 10.7326/0003-4819-73-6-881. [DOI] [PubMed] [Google Scholar]
  28. Dolan M. E., Morimoto K., Pegg A. E. Reduction of O6-alkylguanine-DNA alkyltransferase activity in HeLa cells treated with O6-alkylguanines. Cancer Res. 1985 Dec;45(12 Pt 1):6413–6417. [PubMed] [Google Scholar]
  29. Domoradzki J., Pegg A. E., Dolan M. E., Maher V. M., McCormick J. J. Depletion of O6-methylguanine-DNA-methyltransferase in human fibroblasts increases the mutagenic response to N-methyl-N'-nitro-N-nitrosoguanidine. Carcinogenesis. 1985 Dec;6(12):1823–1826. doi: 10.1093/carcin/6.12.1823. [DOI] [PubMed] [Google Scholar]
  30. Dugle D. L., Gillespie C. J., Chapman J. D. DNA strand breaks, repair, and survival in x-irradiated mammalian cells. Proc Natl Acad Sci U S A. 1976 Mar;73(3):809–812. doi: 10.1073/pnas.73.3.809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Edmonson J. H., Green S. J., Ivins J. C., Gilchrist G. S., Creagan E. T., Pritchard D. J., Smithson W. A., Dahlin D. C., Taylor W. F. A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol. 1984 Mar;2(3):152–156. doi: 10.1200/JCO.1984.2.3.152. [DOI] [PubMed] [Google Scholar]
  32. Einhorn L. H., Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977 Sep;87(3):293–298. doi: 10.7326/0003-4819-87-3-293. [DOI] [PubMed] [Google Scholar]
  33. Ensminger W. D., Rosowsky A., Raso V., Levin D. C., Glode M., Come S., Steele G., Frei E., 3rd A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res. 1978 Nov;38(11 Pt 1):3784–3792. [PubMed] [Google Scholar]
  34. Erickson L. C., Laurent G., Sharkey N. A., Kohn K. W. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature. 1980 Dec 25;288(5792):727–729. doi: 10.1038/288727a0. [DOI] [PubMed] [Google Scholar]
  35. Evans A. E., Gilbert E. S., Zandstra R. The increasing incidence of central nervous system leukemia in children. (Children's Cancer Study Group A). Cancer. 1970 Aug;26(2):404–409. doi: 10.1002/1097-0142(197008)26:2<404::aid-cncr2820260222>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  36. Fisher B., Slack N., Katrych D., Wolmark N. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet. 1975 Apr;140(4):528–534. [PubMed] [Google Scholar]
  37. Frei E., 3rd, Canellos G. P. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980 Oct;69(4):585–594. doi: 10.1016/0002-9343(80)90472-6. [DOI] [PubMed] [Google Scholar]
  38. Frei E., 3rd Curative cancer chemotherapy. Cancer Res. 1985 Dec;45(12 Pt 1):6523–6537. [PubMed] [Google Scholar]
  39. Gee T. S., Yu K. P., Clarkson B. D. Treatment of adult acute leukemia with arabinosylcytosine and thioguanine. Cancer. 1969 May;23(5):1019–1032. doi: 10.1002/1097-0142(196905)23:5<1019::aid-cncr2820230506>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  40. Gibbs J. B., Sigal I. S., Poe M., Scolnick E. M. Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci U S A. 1984 Sep;81(18):5704–5708. doi: 10.1073/pnas.81.18.5704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Goulian M., Bleile B., Tseng B. Y. Methotrexate-induced misincorporation of uracil into DNA. Proc Natl Acad Sci U S A. 1980 Apr;77(4):1956–1960. doi: 10.1073/pnas.77.4.1956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Green J. A., Vistica D. T., Young R. C., Hamilton T. C., Rogan A. M., Ozols R. F. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 1984 Nov;44(11):5427–5431. [PubMed] [Google Scholar]
  43. Griffith O. W., Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem. 1979 Aug 25;254(16):7558–7560. [PubMed] [Google Scholar]
  44. HERTZ R., LI M. C., SPENCER D. B. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med. 1956 Nov;93(2):361–366. doi: 10.3181/00379727-93-22757. [DOI] [PubMed] [Google Scholar]
  45. Harris A. L., Karran P., Lindahl T. O6-Methylguanine-DNA methyltransferase of human lymphoid cells: structural and kinetic properties and absence in repair-deficient cells. Cancer Res. 1983 Jul;43(7):3247–3252. [PubMed] [Google Scholar]
  46. Hayaishi O., Ueda K. Poly(ADP-ribose) and ADP-ribosylation of proteins. Annu Rev Biochem. 1977;46:95–116. doi: 10.1146/annurev.bi.46.070177.000523. [DOI] [PubMed] [Google Scholar]
  47. Heppner G. H., Dexter D. L., DeNucci T., Miller F. R., Calabresi P. Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res. 1978 Nov;38(11 Pt 1):3758–3763. [PubMed] [Google Scholar]
  48. Kohn K. W. Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas. Cancer Res. 1977 May;37(5):1450–1454. [PubMed] [Google Scholar]
  49. Krementz E. T. Lucy Wortham James lecture. Regional perfusion. Current sophistication, what next? Cancer. 1986 Feb 1;57(3):416–432. doi: 10.1002/1097-0142(19860201)57:3<416::aid-cncr2820570304>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  50. Lazarus H. M., Herzig R. H., Graham-Pole J., Wolff S. N., Phillips G. L., Strandjord S., Hurd D., Forman W., Gordon E. M., Coccia P. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol. 1983 Jun;1(6):359–367. doi: 10.1200/JCO.1983.1.6.359. [DOI] [PubMed] [Google Scholar]
  51. Lonsdale D., Gehan E. A., Fernbach D. J., Sullivan M. P., Lane D. M., Ragab A. H. Interrupted vs. continued maintenance therapy in childhood acute leukemia. Cancer. 1975 Aug;36(2):341–352. doi: 10.1002/1097-0142(197508)36:2<341::aid-cncr2820360208>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  52. Louie K. G., Behrens B. C., Kinsella T. J., Hamilton T. C., Grotzinger K. R., McKoy W. M., Winker M. A., Ozols R. F. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res. 1985 May;45(5):2110–2115. [PubMed] [Google Scholar]
  53. MacDonald J. S., Schein P. S., Woolley P. V., Smythe T., Ueno W., Hoth D., Smith F., Boiron M., Gisselbrecht C., Brunet R. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med. 1980 Oct;93(4):533–536. doi: 10.7326/0003-4819-93-4-533. [DOI] [PubMed] [Google Scholar]
  54. Marcove R. C., Miké V., Hajek J. V., Levin A. G., Hutter R. V. Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. J Bone Joint Surg Am. 1970 Apr;52(3):411–423. [PubMed] [Google Scholar]
  55. Martin D. S., Stolfi R. L., Sawyer R. C., Nayak R., Spiegelman S., Young C. W., Woodcock T. An overview of thymidine. Cancer. 1980 Mar 15;45(5 Suppl):1117–1128. doi: 10.1002/1097-0142(19800315)45:5+<1117::aid-cncr2820451316>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  56. Martin D. S., Stolfi R. L., Sawyer R. C., Spiegelman S., Casper E. S., Young C. W. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance. Cancer Res. 1983 May;43(5):2317–2321. [PubMed] [Google Scholar]
  57. Momparler R. L. Kinetic and template studies with 1- -D-arabinofuranosylcytosine 5'-triphosphate and mammalian deoxyribonucleic acid polymerase. Mol Pharmacol. 1972 May;8(3):362–370. [PubMed] [Google Scholar]
  58. OSBORN M. J., FREEMAN M., HUENNEKENS F. M. Inhibition of dihydrofolic reductase by aminopterin and amethopterin. Proc Soc Exp Biol Med. 1958 Feb;97(2):429–431. doi: 10.3181/00379727-97-23764. [DOI] [PubMed] [Google Scholar]
  59. Owellen R. J., Hartke C. A., Dickerson R. M., Hains F. O. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class. Cancer Res. 1976 Apr;36(4):1499–1502. [PubMed] [Google Scholar]
  60. Ozols R. F., Myers C. E., Young R. C. Intraperitoneal chemotherapy. Ann Intern Med. 1984 Jul;101(1):118–120. doi: 10.7326/0003-4819-101-1-118. [DOI] [PubMed] [Google Scholar]
  61. Pegg A. E., Roberfroid M., von Bahr C., Foote R. S., Mitra S., Bresil H., Likhachev A., Montesano R. Removal of O6-methylguanine from DNA by human liver fractions. Proc Natl Acad Sci U S A. 1982 Sep;79(17):5162–5165. doi: 10.1073/pnas.79.17.5162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Pegg A. E., Wiest L., Foote R. S., Mitra S., Perry W. Purification and properties of O6-methylguanine-DNA transmethylase from rat liver. J Biol Chem. 1983 Feb 25;258(4):2327–2333. [PubMed] [Google Scholar]
  63. Phillips G. L., Herzig R. H., Lazarus H. M., Fay J. W., Wolff S. N., Mill W. B., Lin H., Thomas P. R., Glasgow G. P., Shina D. C. Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow. N Engl J Med. 1984 Jun 14;310(24):1557–1561. doi: 10.1056/NEJM198406143102403. [DOI] [PubMed] [Google Scholar]
  64. Rivera G., Pratt C. B., Aur R. J., Verzosa M., Hustu H. O. Recurrent childhood lymphocytic leukemia following cessation of therapy: treatment and response. Cancer. 1976 Apr;37(4):1679–1686. doi: 10.1002/1097-0142(197604)37:4<1679::aid-cncr2820370411>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  65. Ross W., Rowe T., Glisson B., Yalowich J., Liu L. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res. 1984 Dec;44(12 Pt 1):5857–5860. [PubMed] [Google Scholar]
  66. SKIPPER H. E., SCHABEL F. M., Jr, WILCOX W. S. EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. Cancer Chemother Rep. 1964 Feb;35:1–111. [PubMed] [Google Scholar]
  67. Santoro A., Bonfante V., Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med. 1982 Feb;96(2):139–143. doi: 10.7326/0003-4819-96-2-139. [DOI] [PubMed] [Google Scholar]
  68. Sartorelli A. C. Approaches to the combination chemotherapy of transplantable neoplasms. Prog Exp Tumor Res. 1965;6:228–288. doi: 10.1159/000391373. [DOI] [PubMed] [Google Scholar]
  69. Schraufstätter I. U., Hinshaw D. B., Hyslop P. A., Spragg R. G., Cochrane C. G. Glutathione cycle activity and pyridine nucleotide levels in oxidant-induced injury of cells. J Clin Invest. 1985 Sep;76(3):1131–1139. doi: 10.1172/JCI112068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Seto S., Carrera C. J., Kubota M., Wasson D. B., Carson D. A. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest. 1985 Feb;75(2):377–383. doi: 10.1172/JCI111710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Sims J. L., Berger S. J., Berger N. A. Poly(ADP-ribose) Polymerase inhibitors preserve nicotinamide adenine dinucleotide and adenosine 5'-triphosphate pools in DNA-damaged cells: mechanism of stimulation of unscheduled DNA synthesis. Biochemistry. 1983 Oct 25;22(22):5188–5194. doi: 10.1021/bi00291a019. [DOI] [PubMed] [Google Scholar]
  72. Skipper H. E., Schabel F. M., Jr, Mellett L. B., Montgomery J. A., Wilkoff L. J., Lloyd H. H., Brockman R. W. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep. 1970 Dec;54(6):431–450. [PubMed] [Google Scholar]
  73. Smalley R. V., Carpenter J., Bartolucci A., Vogel C., Krauss S. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project. Cancer. 1977 Aug;40(2):625–632. doi: 10.1002/1097-0142(197708)40:2<625::aid-cncr2820400206>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  74. Spitzer G., Farha P., Valdivieso M., Dicke K., Zander A., Vellekoop L., Murphy W. K., Dhingra H. M., Umsawasdi T., Chiuten D. High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. J Clin Oncol. 1986 Jan;4(1):4–13. doi: 10.1200/JCO.1986.4.1.4. [DOI] [PubMed] [Google Scholar]
  75. Strauss B. S. Cellular aspects of DNA repair. Adv Cancer Res. 1985;45:45–105. doi: 10.1016/s0065-230x(08)60266-3. [DOI] [PubMed] [Google Scholar]
  76. Thomas E. D. Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases. J Clin Oncol. 1983 Sep;1(9):517–531. doi: 10.1200/JCO.1983.1.9.517. [DOI] [PubMed] [Google Scholar]
  77. Tong W. P., Kirk M. C., Ludlum D. B. Molecular pharmacology of the haloethyl nitrosoureas: formation of 6-hydroxyethylguanine in DNA treated with BCNU (N,N1-bis[2-chloroethyl]-N-nitrosourea). Biochem Biophys Res Commun. 1981 May 15;100(1):351–357. doi: 10.1016/s0006-291x(81)80103-9. [DOI] [PubMed] [Google Scholar]
  78. Valagussa P., Bonadonna G., Veronesi U. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer. 1978 Mar;41(3):1170–1178. doi: 10.1002/1097-0142(197803)41:3<1170::aid-cncr2820410355>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  79. Valeriote F. A., Edelstein M. B. The role of cell kinetics in cancer chemotherapy. Semin Oncol. 1977 Jun;4(2):217–226. [PubMed] [Google Scholar]
  80. Valeriote F., Lin H. s. Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother Rep. 1975 Sep-Oct;59(5):895–900. [PubMed] [Google Scholar]
  81. Vaughan W. P., Karp J. E., Burke P. J. Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood. 1984 Nov;64(5):975–980. [PubMed] [Google Scholar]
  82. Yarosh D. B., Rice M., Day R. S., 3rd, Foote R. S., Mitra S. O6-Methylguanine-DNA methyltransferase in human cells. Mutat Res. 1984 Jan;131(1):27–36. doi: 10.1016/0167-8817(84)90044-0. [DOI] [PubMed] [Google Scholar]
  83. Zaharko D. S., Fung W. P., Yang K. H. Relative biochemical aspects of low and high doses of methotrexate in mice. Cancer Res. 1977 Jun;37(6):1602–1607. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES